Alzheimer's Disease Education and Referral Center

Alzheimer's Disease Neuroimaging Study 2 (ADNI2) Now Recruiting

A Landmark Research Study Sponsored by the National Institutes of Health

Your participation in this research may help us learn how to stop the progression of mild cognitive impairment (MCI) and Alzheimer’s disease in future generations. Information from the study might, in the future, lead to new treatments.

Volunteer in ADNI/List of ADNI sites »

View videos on participating in ADNI »

Researchers are looking for 550 volunteers between the ages of 55 and 90:

150 with mild Alzheimer’s disease
100 with early mild cognitive impairment (eMCI)
150 with late mild cognitive impairment (lMCI)
150 with no apparent memory problems

All ADNI2 volunteers should be:

In good general health
Fluent in English or Spanish
Willing and able to undergo the test procedures
Accompanied by a study partner – a friend or relative who can go with the volunteer to all clinic visits and has at least 10 hours of contact per week with the volunteer.

Participants may volunteer at 58 sites across the United States.
Full description and list of study sites

The Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) is an extension of the original ADNI study, which began in 2004, and ADNI-GO, which began in 2010. ADNI uses neuroimaging and biomarker measures to track the changes taking place in the brains of 800 older people either free of symptoms or diagnosed with late-stage mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). The goal of ADNI-GO was to use imaging techniques and biomarkers found in blood and cerebrospinal fluid to identify AD at a pre-dementia stage. The ADNI-GO effort, funded through the American Recovery and Reinvestment Act, enabled researchers to continue studying nearly 500 of the original ADNI volunteers, while expanding the study to include the new participants with early MCI (EMCI), a condition that may progress to AD.

ADNI2 extends the work of ADNI1 and ADNI-GO to understand the progression of AD. The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD, as the pathology evolves from normal aging through very mild symptoms, to MCI, to dementia.